Aggressive Stock Portfolio: 5 Stocks Picked by Analysts

3. NovoCure Limited (NASDAQ:NVCR)

Average Analyst Price Target as of March 28: $26.43

Upside Potential as of March 28: 69.10%

Number of Hedge Fund Holders: 29

Root, Switzerland-based NovoCure Limited (NASDAQ:NVCR) is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields.

The portfolio of NovoCure Limited (NASDAQ:NVCR) includes products approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma, and pleural mesothelioma. Its clinical trials pipeline includes Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

NovoCure Limited (NASDAQ:NVCR) is expecting top-line data from the phase 3 METIS clinical trial in brain metastases by the end of Q1 2024. Earlier in January, the FDA accepted the Premarket Approval (PMA) application seeking approval for the use of TTFields therapy together with standard therapies for the treatment of NSCLC.